Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

No progression in joint damage in 84% of psoriatic arthritis patients

No progression in joint damage in 84% of psoriatic arthritis patients

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Results of IPC survey identifying 21 psoriasis research priorities published in British Journal of Dermatology

Results of IPC survey identifying 21 psoriasis research priorities published in British Journal of Dermatology

National Psoriasis Foundation introduces patient-centered research network

National Psoriasis Foundation introduces patient-centered research network

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

National Psoriasis Foundation awards grants to support psoriatic disease research

National Psoriasis Foundation awards grants to support psoriatic disease research

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets